Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 56

Sort by

Sort Order Select

Journal Articles

CYP3A inhibitors and impact of these agents on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine on the VIALE-A study

Brian A Jonas, MD PhD, Courtney D. Dinardo, MDMSc, Nicola Fracchiolla, Alexander Pristupa, MD, Kenichi Ishizawa, MD PhD, Jie Jin, MD PhD, Marina Konopleva, MD PhD, Yishai Ofran, Pau Montesinos, MD PhD, Tibor Kovacsovics, MD, Jun-Ho Jang, MD, Hagop M. Kantarjian, MD, Wan-Jen Hong, MD, Yinghui Duan, PhD, William Ainsworth, Jalaja Potluri, MD, Michael Werner, Anders Erik Svensson, MD, Keith W. Pratz, MD

Blood (2020) 136 (Supplement 1): 50–52.

https://doi.org/10.1182/blood-2020-134850

Published: 2020

Journal Articles

Imerge: A Phase 3 Study to Evaluate Imetelstat in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Blood (2020) 136 (Supplement 1): 17.

https://doi.org/10.1182/blood-2020-138810

Published: 2020

Journal Articles

Transfusion Requirements in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria with or without a History of Bone Marrow Disorder Receiving Ravulizumab and Eculizumab: Results from a Phase 3 Non-Inferiority Study Extension

Antonio Risitano, Jun-Ho Jang, MD, Lee Gyeong-Won, Wanchai Wanachiwanawin, Hubert Schrezenmeier, Yuji Yonemura, MDPhD, Talha Munir, MBBS, Rodrigo Pavani, Jimmy Wang, Alexander D. Kulagin, MD PhD, Austin Kulasekararaj, MDMBBS,MRCP,FRCPath, Flore Sicre de Fontbrune, Alexander Röth, MD

Blood (2020) 136 (Supplement 1): 31–33.

https://doi.org/10.1182/blood-2020-140418

Published: 2020

Journal Articles

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission

Blood (2019) 134 (Supplement_2): LBA-3.

https://doi.org/10.1182/blood-2019-132405

Published: 2019

Journal Articles

AGILE: A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Ivosidenib in Combination with Azacitidine in Adult Patients with Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation

Pau Montesinos Fernandez, MD PhD, Christian Recher, MD PhD, Vadim Doronin, MD, Rodrigo T. Calado, MD PhD, Jun Ho Jang, MD PhD, Yasushi Miyazaki, MD PhD, Jianxiang Wang, MD, Diego A Gianolio, PhD, Scott R. Daigle, MS, Thomas Winkler, MD, Vickie Zhang, PhD, Peter Paschka, MD

Blood (2019) 134 (Supplement_1): 2593.

https://doi.org/10.1182/blood-2019-123045

Published: 2019

Journal Articles

Prophylactic Antibiotic Use and Risk of Meningococcal Infections in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Treated with Eculizumab Who Received Meningococcal Vaccination: Results from the International PNH Registry

Christopher J. Patriquin, MDFRCPC,MSc, Austin Kulasekararaj, MDMBBS,MRCP,FRCPath, Régis Peffault de Latour, MD PhD, Jun-Ho Jang, MD PhD, Saskia Langemeijer, MD PhD, Alexey A. Maschan, MD, Amanda Wilson, PhD, Deepak Jain, Jaroslaw P. Maciejewski, MD PhD

Blood (2019) 134 (Supplement_1): 4802.

https://doi.org/10.1182/blood-2019-127005

Published: 2019

Journal Articles

Randomized Trial of Two Dosages of Rabbit Antithymocyte Globulin in Patients with Aplastic Anemia

Atsushi Narita, MD PhD, Xiaofan Zhu, PhD, Hideki Muramatsu, MD PhD, Xiaojuan Chen, Ye Guo, Wenyu Yang, Jingliao Zhang, MD, Fang Liu, Jun Ho Jang, MD PhD, Hoon Kook, MD PhD, Hawk Kim, MD PhD, Kensuke Usuki, MD PhD, Hirohito Yamazaki, MD PhD, Yoshiyuki Takahashi, MD, PhD, Shinji Nakao, MD PhD, Jong-Wook Lee, MD PhD, Seiji Kojima, MD PhD

Blood (2018) 132 (Supplement 1): 3873.

https://doi.org/10.1182/blood-2018-99-111323

Published: 2018

Journal Articles

Clinical Relevance of Diagnostic Criteria for Hemophagocytic Lymphohistiocytosis (HLH) and Survival Outcome of Adult HLH Patients: A Single-Center Prospective Cohort Study

Joon Young Hur, MD, Kang Kook Lee, MD, Jun Ho Jang, MD PhD, Kihyun Kim, MD PhD, Chul Won Jung, MD PhD, Won Seog Kim, MD PhD, Seok Jin Kim, MD PhD

Blood (2018) 132 (Supplement 1): 3718.

https://doi.org/10.1182/blood-2018-99-114858

Published: 2018

Journal Articles

Ravulizumab (ALXN1210) Versus Eculizumab in Adults with Paroxysmal Nocturnal Hemoglobinuria: Pharmacokinetics and Pharmacodynamics Observed in Two Phase 3 Randomized, Multicenter Studies

Regis Peffault De Latour, Robert A. Brodsky, MD, Stephan Ortiz, RPh, PhD, Antonio M. Risitano, MD PhD, Jun-Ho Jang, MD PhD, Peter Hillmen, MB ChB, PhD FRCP, FRCPath, Aleksandr Kulagin, Rajendra Pradhan, PhD, Scott T. Rottinghaus, MD, Rasha Aguzzi, MS, Richard A. Wells, MD DPhil, Jeffrey Szer, MBBS

Blood (2018) 132 (Supplement 1): 626.

https://doi.org/10.1182/blood-2018-99-110858

Published: 2018

Journal Articles

Bortezomib-Based First Line Treatment for AL Amyloidosis Patients Who Are Not Candidate for Stem Cell Transplantaion

Joon Young Hur, MD, Kang Kook Lee, MD, Sang Eun Yoon, MD, Sehhoon Park, MD, Jangho Cho, MD, Youjin Kim, MD, Eunseok Jeon, MD PhD, Jinoh Choi, MD PhD, Gayeon Lee, MD PhD, Byungjun Kim, MD PhD, Ju Hong Min, MD PhD, Jung Sun Kim, MD PhD, Jung Eun Lee, MD PhD, Joon Young Choi, MD PhD, Seok Jin Kim, MD PhD, Jun Ho Jang, MD PhD, Won-Seog Kim, MD PhD, Chul Won Jung, MD PhD, Kihyun Kim, MD PhD

Blood (2018) 132 (Supplement 1): 3256.

https://doi.org/10.1182/blood-2018-99-114099

Published: 2018

Journal Articles

Efficacy and Safety of Romiplostim in Patients with Acquired Aplastic Anemia Ineligible or Refractory to Immunosuppressive Therapy: Interim Analysis of Phase 2/3 Clinical Trial

Blood (2018) 132 (Supplement 1): 1306.

https://doi.org/10.1182/blood-2018-99-112478

Published: 2018

Journal Articles

Imetelstat Treatment Leads to Durable Transfusion Independence (TI) in RBC Transfusion-Dependent (TD), Non-Del(5q) Lower Risk MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Who Are Lenalidomide (LEN) and HMA Naive

David P. Steensma, Uwe Platzbecker, Koen Van Eygen, Azra Raza, MD, Valeria Santini, Ulrich Germing, MD, Patricia Font, MD, Irina Samarina, MD, Maria Díez-Campelo, Sylvain Thepot, MD, Edo Vellenga, Mrinal M. Patnaik, MDMBBS, Jun Ho Jang, MD PhD, Jacqueline Bussolari, PhD, Laurie Sherman, BSN, Libo Sun, PhD, Helen Varsos, MS, RPh, Esther Rose, MD, Pierre Fenaux

Blood (2018) 132 (Supplement 1): 463.

https://doi.org/10.1182/blood-2018-99-114877

Published: 2018

Journal Articles

Current Status and Optimal Management of Eculizumab Poor-Responders Due to C5 Polymorphisms

Yasutaka Ueda, MD PhD, Hiroyuki Takamori, MD, Jun-Ho Jang, MD PhD, Chezi Ganzel, MD, Saskia Langemeijer, MD PhD, Makiko Osato, MS, Petra Muus, MD PhD, Jong-Wook Lee, MD PhD, Jun-Ichi Nishimura, MD PhD, Yuzuru Kanakura, MD PhD

Blood (2018) 132 (Supplement 1): 2323.

https://doi.org/10.1182/blood-2018-99-111230

Published: 2018

Journal Articles

Comparison of Baseline Clinical Characteristics between Asian Vs. Non-Asian Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) from International PNH Registry

Jun Ho Jang, MD PhD, Shinichiro Okamoto, MD PhD, Masatoshi Sakurai, MD, Wen-Chien Chou, MD, PhD, Jin Seok Kim, MD PhD, Amanda Wilson, MPH, PhD, Jun-Ichi Nishimura, MD PhD, Tzeon-Jye Chiou, MD, Jong-Wook Lee, MD, Yuzuru Kanakura, MD PhD

Blood (2017) 130 (Supplement 1): 3472.

https://doi.org/10.1182/blood.V130.Suppl_1.3472.3472

Published: 2017

Journal Articles

Intravenous Iron Supplementation Alone for Treatment of Anemia in Cancer Patients

Silvia Park, Chul W. Jung, MD PhD, Jun Ho Jang, MD PhD

Blood (2017) 130 (Supplement 1): 4756.

https://doi.org/10.1182/blood.V130.Suppl_1.4756.4756

Published: 2017

Journal Articles

International ITP Registry with Focus on the Asia Pacific Region: Update on Preliminary Findings of Epidemiological and Clinical Data

Beng H Chong, MBBS, PhD, Jong-Wook Lee, MD, Jun Ho Jang, MD PhD, Tzeon-Jye Chiou, MD, Lai Heng Lee, Osman Ilhan, MD, Pantep Angchaisuksiri, MD, Ai-Sim Goh, Soo Chin Ng, FRCP, Shinichiro Okamoto, MD, Kenny Mauricio Galvez, Sarah Davidson, RN

Blood (2017) 130 (Supplement 1): 4853.

https://doi.org/10.1182/blood.V130.Suppl_1.4853.4853

Published: 2017

Journal Articles

ITP Patients in the Asia Pacific: Are They Different?

Beng H Chong, MBBS, PhD, Jong-Wook Lee, MD, Jun Ho Jang, MD PhD, Tzeon-Jye Chiou, MD, Lai Heng Lee, Osman Ilhan, MD, Pantep Angchaisuksiri, MD, Kenny Mauricio Galvez, Ai-Sim Goh, Soo Chin Ng, FRCP, Shinichiro Okamoto, MD, Sarah Davidson, RN

Blood (2017) 130 (Supplement 1): 4862.

https://doi.org/10.1182/blood.V130.Suppl_1.4862.4862

Published: 2017

Journal Articles

Efficacy of Bortezomib-Based Regimens for Patients with Newly Diagnosed AL Amyloidosis Not Receiving ASCT Compared with Alkylators and Dexamethasone-Based Regimens

Blood (2017) 130 (Supplement 1): 3114.

https://doi.org/10.1182/blood.V130.Suppl_1.3114.3114

Published: 2017

Journal Articles

Clinical Outcomes of Decitabine Treatment for Patients with Lower-Risk Myelodysplastic Syndrome By the International Prognostic Scoring System

Ki Sun Jung, Jun Ho Jang, MD PhD, Je-Hwan Lee, MD PhD

Blood (2017) 130 (Supplement 1): 1697.

https://doi.org/10.1182/blood.V130.Suppl_1.1697.1697

Published: 2017

Journal Articles

Optimization of Dose Regimen for ALXN1210, a Novel Complement C5 Inhibitor, in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Results of 2 Phase 1/2 Studies

Alexander Roeth, MD, Scott T. Rottinghaus, MD, Anita Hill, MBChB (Hons), PhD, Jin Seok Kim, MD PhD, Hubert Schrezenmeier, MD, Louis Terriou, MD, Alvaro Urbano-Ispizua, MD, Richard A. Wells, MD DPhil, Jun Ho Jang, MD PhD, Jeff Szer, MB, BS, FRACP, Rasha Aguzzi, MS, Eric Scott Bachman, MD PhD, Andrew I. Damokosh, PhD, Lori Shafner, PhD, Jong-Wook Lee, MD

Blood (2017) 130 (Supplement 1): 3482.

https://doi.org/10.1182/blood.V130.Suppl_1.3482.3482

Published: 2017

NARROW

CYP3A inhibitors and impact of these agents on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine on the VIALE-A study

Imerge: A Phase 3 Study to Evaluate Imetelstat in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Transfusion Requirements in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria with or without a History of Bone Marrow Disorder Receiving Ravulizumab and Eculizumab: Results from a Phase 3 Non-Inferiority Study Extension

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission

AGILE: A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Ivosidenib in Combination with Azacitidine in Adult Patients with Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation

Prophylactic Antibiotic Use and Risk of Meningococcal Infections in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Treated with Eculizumab Who Received Meningococcal Vaccination: Results from the International PNH Registry

Randomized Trial of Two Dosages of Rabbit Antithymocyte Globulin in Patients with Aplastic Anemia

Clinical Relevance of Diagnostic Criteria for Hemophagocytic Lymphohistiocytosis (HLH) and Survival Outcome of Adult HLH Patients: A Single-Center Prospective Cohort Study

Ravulizumab (ALXN1210) Versus Eculizumab in Adults with Paroxysmal Nocturnal Hemoglobinuria: Pharmacokinetics and Pharmacodynamics Observed in Two Phase 3 Randomized, Multicenter Studies

Bortezomib-Based First Line Treatment for AL Amyloidosis Patients Who Are Not Candidate for Stem Cell Transplantaion

Efficacy and Safety of Romiplostim in Patients with Acquired Aplastic Anemia Ineligible or Refractory to Immunosuppressive Therapy: Interim Analysis of Phase 2/3 Clinical Trial

Imetelstat Treatment Leads to Durable Transfusion Independence (TI) in RBC Transfusion-Dependent (TD), Non-Del(5q) Lower Risk MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Who Are Lenalidomide (LEN) and HMA Naive

Current Status and Optimal Management of Eculizumab Poor-Responders Due to C5 Polymorphisms

Comparison of Baseline Clinical Characteristics between Asian Vs. Non-Asian Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) from International PNH Registry

Intravenous Iron Supplementation Alone for Treatment of Anemia in Cancer Patients

International ITP Registry with Focus on the Asia Pacific Region: Update on Preliminary Findings of Epidemiological and Clinical Data

ITP Patients in the Asia Pacific: Are They Different?

Efficacy of Bortezomib-Based Regimens for Patients with Newly Diagnosed AL Amyloidosis Not Receiving ASCT Compared with Alkylators and Dexamethasone-Based Regimens

Clinical Outcomes of Decitabine Treatment for Patients with Lower-Risk Myelodysplastic Syndrome By the International Prognostic Scoring System

Optimization of Dose Regimen for ALXN1210, a Novel Complement C5 Inhibitor, in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Results of 2 Phase 1/2 Studies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only